MMP13 and gastric cancer: We used bsPD-L1 and MMP13 to categorize GC patients into three groups: (i) bsPD-L1− (immune-silent phenotype), (ii) bsPD-L1+MMP13low (immune-activated phenotype with ECM integrity), and (iii) bsPD-L1+MMP13high (immune-activated phenotype without ECM integrity).